Login to Your Account



CV Therapeutics' Phase III Strong With Regadenoson

By Randall Osborne


Friday, August 12, 2005
CV Therapeutics Inc.'s regadenoson to boost coronary blood flow for better myocardial perfusion imaging hit the primary endpoint in the first of two pivotal Phase III studies, and the company is awaiting results from the second trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription